Viatris raises 2026 revenue guidance to $14.55 bln-$14.95 bln
Company expects 2026 adjusted EPS of $2.45-$2.59
Viatris anticipates $100 mln-$150 mln revenue impact from Nashik supply disruptions in H2 2026
Overview
Healthcare company's Q2 revenue rose 5%, beating analyst expectations
Adjusted EPS for Q2 up 11%, beating analyst expectations
Company returned about $550 mln to shareholders, including share repurchases
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$3.76 bln
$3.68 bln (6 Analysts)
Q2 Adjusted EPS
Beat
$0.69
$0.60 (7 Analysts)
Q2 Loss Per Share
$0.10
Q2 Net Loss
$118.80 mln
Result drivers
New product sales - Co said Q2 revenue growth was primarily driven by new product sales in Developed Markets and strong growth in Greater China
- Brands net sales reflected continued strength in Greater China and Emerging Markets, while generics net sales benefited from new launches and growth in Developed Markets, partly offset by supply constraints in the ARV business within Emerging Markets
Non-cash charge - Q2 net loss was primarily driven by a non-cash charge related to the planned sale of Tyrvaya product rights and the write down of that intangible asset
VTRS•
